Cosunter(300436)2025-01-21 10:54Financial Performance Expectations - The company expects a total profit loss between RMB 13,000,000 and RMB 16,800,000 for the year 2024, compared to a loss of RMB 29,802,910 in the previous year[4]. - The net profit attributable to shareholders is projected to be a loss between RMB 12,500,000 and RMB 16,300,000, down from a loss of RMB 34,858,980 in the same period last year[4]. - The operating revenue is estimated to be between RMB 43,500,000 and RMB 46,000,000, an increase from RMB 42,271,490 in the previous year[4]. - The net profit after deducting non-recurring gains and losses is expected to be a loss between RMB 15,700,000 and RMB 19,500,000, compared to a loss of RMB 35,423,280 last year[4]. - The company anticipates that non-recurring gains and losses will impact the net profit attributable to shareholders by approximately RMB 3,200,000[7]. - The final financial data for 2024 will be disclosed in the annual report, urging investors to make cautious decisions[8]. - The company has communicated with the accounting firm regarding the preliminary financial data, with no significant discrepancies noted[5]. Business Strategy and Operations - The company is actively expanding its market presence while implementing cost reduction and efficiency improvement strategies[7]. - Increased sales, management, and financial expenses are attributed to enhanced market promotion and team building efforts, alongside significant fixed asset investments[7]. - The company is continuing to advance clinical research for innovative drugs, resulting in a high proportion of R&D expenses[7].